Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Pharmaceutical preparation of biflavone compound for anti gout

A pharmaceutical preparation, biflavone technology, applied in the field of anti-gout bisflavonoid pharmaceutical preparations, can solve the problems of poor water solubility or fat solubility, limited curative effect, and low dispersion

Inactive Publication Date: 2007-10-10
湖北中医学院
View PDF0 Cites 11 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The second fact is that although the monomers of some components in these biflavone compounds have higher inhibitory potency to xanthine oxidase, their pure products are not good in water solubility or fat solubility, so the dispersion is not good. High, the efficacy is still limited, it is necessary to improve the solubility through derivatization

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical preparation of biflavone compound for anti gout

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0015] Example 1 Experiments of Biflavone Compounds and Compositions Inhibiting Xanthine Oxidase in Vitro

[0016] 1.1 Sample materials, reagents

[0017] Biflavone, Robustaflavone, Robustaflavone-4'--methyl ether and other bisflavone compounds are monomers isolated from medicinal plants of the genus Selaginella in the laboratory of Hubei University of Traditional Chinese Medicine The compound is confirmed by structural identification, and the content is more than 97% calculated by the normalization method. The biflavonoid compound composition is a medicinal plant extract mainly containing various biflavonoid compounds extracted from medicinal plants, and its total flavonoid content is 35% to 45%. See Table 1 for the ratios of robusta flavone and robusta flavone-4'-methyl ether.

[0018] make up

combination

Suohua fir pair

Relative content of flavonoids%

Loposta Biflavone Phase

For content%

Roposta Biflavone-

4'-...

Embodiment 2

[0038] Example 2, the experiment of biflavone compound and its composition inhibiting lipoxygenase in vitro

[0039] 2.1 Materials, instruments and reagents

[0040] The composition of biflavone compound and several biflavone compounds is the same as in Example 1.

[0041] Instruments and Reagents DU640 Spectrophotometer (Beckman Inc. USA) with kinetic / time software. Lipoxygenase LOX (Sigma, lot118F03422), linoleic acid (Sigma, lot015K1200); quercetin (10081-9906); dimethyl sulfoxide and Tween-20 (Tween-20 Amresco), and other reagents were of analytical grade .

[0042] 2.2 Method

[0043] 2.2.1 Test solution preparation: 3.3 mmol / L substrate solution: Take 157.2 microliters of linoleic acid, 157.2 microliters of Tween-20 (Tween-20), 10 milliliters of water, and add 0.5 milliliters of 1 mol / liter NaOH Make the solution clear, add water to 25 ml, mix well to obtain substrate stock solution. The substrate stock solution was diluted with 0.2 mol / L phosphate buffer solution t...

Embodiment 3

[0055] Embodiment 3, the pharmacodynamic experiment of anti-hyperuricemia in vivo

[0056] 3.1 Experimental materials

[0057] Male Kunming mice, weighing (24±2) grams, were purchased from the Experimental Animal Center of Hubei Province. The 80% ethanol extract of a certain medicinal plant, in which the total flavonoid content is greater than 35%, and the biflavonoid compounds contained in it are Biflavone, Robosta Biflavone, Robosta Biflavone-4'--Methyl Ether The ratio is 75:15:5.

[0058] 2. Experimental method

[0059] 40 male mice were randomly divided into 4 groups, 10 in each group, administered once a day i.g (gavage), for 4 consecutive days, wherein the normal saline group and hyperuricemia model group were dosed i.g. 100 ml / kg every day. Normal saline, hyperuricemia model group received ip (intraperitoneal injection) of oxonic acid potassium salt 2 hours before blood collection, and ip oxonic acid potassium salt in the administration group one hour before the last...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

A bisflavone medicine for preventing and treating gout, preventing the xanthine and hypoxanthine from being oxidized to become uric acid, and relaxing the hyperuricemia and its secondary diseases is prepared from one or more of bisflavone compounds and the auxiliaries.

Description

Technical field [0001] The invention relates to plant extracts containing biflavonoids or derivatives or salts of biflavonoids, which are prepared as medicines for preventing or treating hyperuricemia and gout. Background technique [0002] Gout is a disease caused by a disorder of purine metabolism. The clinical features are hyperuricemia, gouty arthritis, joint deformity, kidney disease, uric acid stones, gout stone formation, etc. Among them, hyperuricemia is a state in which uric acid in the blood exceeds normal, and it is a stage in the development of gout disease; gouty arthritis is that after the serum uric acid level increases, uric acid is deposited in the joint tissue, irritating the joint and causing a series of diseases. Inflammation. [0003] Existing drugs selectively treat the symptoms of gout patients in different periods. For example, anti-inflammatory and analgesic drugs colchicine and indomethacin are used for the treatment of acute attacks of gout; uri...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/352A61P19/06
Inventor 陈科力谭文界徐嘉诚黎莉江雪平范小磊
Owner 湖北中医学院
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com